Covid-19 roundup: Kate Bing­ham to lead UK task­force; Fed­er­al judge to Shkre­li: You’re not go­ing to save the world, ...

6 years ago
Coronavirus

Clo­vis' Rubra­ca wins prostate can­cer ap­proval, but da­ta from ri­val Lyn­parza damp­en com­mer­cial ex­pec­ta­tions

6 years ago
R&D
FDA+

Mon­cef Slaoui piv­ots from Mod­er­na's board to the helm of Project Warp Speed. His task: Overnight suc­cess

6 years ago
People
Bioregnum

J&J jumps in­to gam­ma delta field with La­va col­lab­o­ra­tion; Myokar­dia guns for $605M raise

6 years ago
News Briefing

Look­ing for first-in-class glo­ry, Boehringer In­gel­heim ac­quires two pre­clin­i­cal can­cer drugs from Ver­sant-backed ...

6 years ago
Deals

Rare dis­ease drug­mak­er Ul­tragenyx builds case for its gene ther­a­py fran­chise with fresh tri­al up­dates

6 years ago
R&D
Cell/Gene Tx

Af­ter a PhI­II fail­ure, the FDA de­liv­ers Blue­print an ex­pect­ed CRL

6 years ago
R&D
FDA+

Sanofi scores a snap re­view for a rare dis­ease drug, an­oth­er win for the come­back play­ers in R&D

6 years ago
R&D
FDA+

Cher­ry Thomas joins Cari­bou as SVP of clin­i­cal de­vel­op­ment; Ar­tax locks in Joseph Lobac­ki as CEO

6 years ago
Peer Review

Pfiz­er gene ther­a­py ups lev­els of dy­s­trophin ex­pres­sion in Duchenne tri­al — but an­oth­er safe­ty set­back mars re­sults

6 years ago
R&D
Cell/Gene Tx

Serge Wein­berg is­sues sharp re­ver­sal as board, French gov­ern­ment re­act to CEO Paul Hud­son’s vac­cine re­marks

6 years ago
R&D
Coronavirus

ADC steams back to vir­tu­al Wall Street — and this time the team scores a $233M IPO haul

6 years ago
Financing

Covid-19 roundup: Trump ad­min­is­tra­tion prep­ping ex­ec or­der to re­duce re­liance on for­eign man­u­fac­tur­ing of 'essen­tial ...

6 years ago
Coronavirus

Stan­ford, Park­er In­sti­tute sci­en­tists team up with two young en­gi­neers in $20M AI play with an im­munol­o­gy fo­cus

6 years ago
Financing
AI

Rick Bright de­tails mis­man­aged pan­dem­ic re­sponse, warns of drugs, vac­cine sup­ply prob­lems down the road; HHS push­es ...

6 years ago
People
Coronavirus

ADC up­sizes IPO of­fer­ing in search of a $175M-plus haul; No­vo presents en­cour­ag­ing GLP-1 da­ta from obe­si­ty study

6 years ago
News Briefing

Ex­per­i­men­tal in­jec­tion of 'good' bac­te­ria sig­nif­i­cant­ly cut bac­te­r­i­al vagi­nosis re­cur­rence rate — study

6 years ago
R&D

How the pan­dem­ic helped se­cure a rare can­cer drug for Menar­i­ni

6 years ago
Deals

BIO gets a new chief lob­by­ist to face off against the grow­ing ranks of crit­ics in Con­gress

6 years ago
People
Bioregnum

BC­MA ri­val to blue­bird, Bris­tol My­ers files for $100M IPO as the fron­trun­ners stum­ble in a race to the fin­ish line

6 years ago
Financing
R&D

Covid-19 roundup: Count­ing 1,087 tri­als for coro­n­avirus, R&D ex­perts say much of it is a com­plete waste; WHO ...

6 years ago
Coronavirus

It's Mon­cef Slaoui. Trump ad­min­is­tra­tion set­tles on ex-GSK vac­cines chief as Covid-19 R&D czar — re­ports

6 years ago
People
Coronavirus

Al­lo­gene spot­lights their off-the-shelf CAR-T con­tender ‘501 with a snap­shot on CRs and no GVHD

6 years ago
R&D

Days af­ter rapid FDA ap­proval, Lil­ly and Blue­print go head-to-head again at AS­CO

6 years ago
R&D
First page Previous page 842843844845846847848 Next page Last page
A service from the Financial Times